vaccine – Page 2 – media

Senators Write to GlaxoSmithKline to Boost Shingrix Supply

As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
- Source: FiercePharma
- 818
- July 10, 2018
Company Insight GlaxoSmithKline shingles Shingrix vaccine
Next year’s flu shot will shield only 20% against dominant strain

Recent doubts about traditional egg-based flu shots could mean more business for vaccines manufactured in cells. Protection against the dominant H3N2 flu strain offered by the coming season’s flu vaccine will still be far from optimal—putting it mildly. And that's thanks to the widely used manufacturing process based on eggs, a new study predicts.
- Source: fiercepharma
- 667
- April 24, 2018
H3N2 flu strain Researches vaccine
GSK pharma boss Miels rejigs commercial operations to stoke new launches Trelegy, Shingrix

GlaxoSmithKline's new CEO Emma Walmsley isn’t the only one shaking things up at the top of the British drugmaker.
- Source: fiercepharma.
- 706
- March 23, 2018
Company Insights GlaxoSmithKline Shingrixin vaccine
Participants in rogue herpes vaccine research take legal action

Three people injected with an unauthorized herpes vaccine by a Southern Illinois University researcher have filed suit against his company, demanding compensation for alleged adverse side effects from the experiments.
- Source: fiercepharma
- 597
- March 15, 2018
herpes Researches vaccine
GlaxoSmithKline’s Fluarix protects young children in large phase 3 test

GSK touted phase 3 data of its quadrivalent flu vaccine Fluarix Tetra. As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.
- Source: Fiercepharma
- 752
- March 9, 2018
Clinical Trials flu vaccine
Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to advance public health measures.
- Source: medicalxpress
- 673
- January 22, 2018
smallpox synthetic DNA synthetic virus vaccine
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine

For decades now, investigators have been drawn to HIV vaccine research — a Holy Grail in anti-viral research that would have an enormous impact in a world that still sees two million new infections every year.
- Source: Endpts;
- 517
- December 4, 2017
HIV Market Views vaccine virus
Brief Report on Exports of Chinese Vaccines in the First Three Quarters of 2017

In the first three quarters of 2017, the export sales of Chinese vaccines were 47.12 million USD with a slight increase of 6% over the same period of 2016.
- Source: Ddu
- 1,521
- November 27, 2017
export Market Reports vaccine
POLICY CHANGE! Only 35 Days for New Drug Approvals!

Beijing Beishengyan biological Product’s Sabin Strain Inactivated Polioviurs Vaccine (Sabin IPV), secured approval from the China Food and Drug Administration (CFDA) in August 2017. On September 29th, Sabin IPV was officially on the market, offering one more option for IPV precaution. With the exception of time for material supplements, the CFDA took only 35 days to process production, registration and application of Beishengyan’s IPV and issue a drug approval number and certificate.
- Source: Ddu
- 700
- November 10, 2017
Ddu College drug approval IPV vaccine
Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

As NousCom CEO Alfredo Nicosia likes to say, the Basel-based biotech is a relative fledgling at 2-years of age. But the core research team there has been working together for quite a few years.
- Source: Endpts
- 585
- November 9, 2017
immune Market Views oncology vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.